

Glucose-dependent insulinotropic polypeptide deficiency reduced fat accumulation and insulin resistance, but deteriorated bone loss in ovariectomized mice

Satoko Shimazu-Kuwahara^{1,2†}, Yoshinori Kanemaru^{2†}, Norio Harada² , Eri Ikeguchi², Yohei Ueda², Shunsuke Yamane², Yuki Murata², Akihiro Yasoda², Timothy J Kieffer³, Nobuya Inagaki^{2*} 

¹Preemptive Medicine and Lifestyle-related Disease Research Center, Kyoto University Hospital, ²Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan, and ³Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada

Keywords

Glucose-dependent insulinotropic polypeptide, Obesity, Ovariectomy

*Correspondence

Nobuya Inagaki
Tel.: +81-75-751-3562
Fax: +81-75-771-6601
E-mail address:
inagaki@kuhp.kyoto-u.ac.jp

J Diabetes Investig 2019; 10: 909–914

doi:10.1111/jdi.12978

ABSTRACT

Given the established roles of glucose-dependent insulinotropic polypeptide (GIP) in promoting fat storage and bone formation, we assessed the contribution of GIP to obesity and osteopenia in ovariectomized mice with a gene encoding green fluorescent protein (GFP) inserted into the GIP locus, in which GIP was either reduced ($GIP^{Gfp/+}$) or absent ($GIP^{Gfp/Gfp}$). In $GIP^{Gfp/Gfp}$ mice, weight gain, subcutaneous and visceral fat mass were reduced, and glucose intolerance was improved compared with wild-type mice with the same magnitude of insulin responses. Cancellous bone mineral density and bone cortical thickness were reduced in $GIP^{Gfp/Gfp}$ mice compared with wild-type mice. In $GIP^{Gfp/+}$ mice, weight gain, glucose intolerance and cancellous bone mineral density were not different from that of wild-type mice. These results indicate that the total elimination of GIP ameliorates weight gain and adiposity in ovariectomized mice, but it enhances osteopenia, particularly in cancellous bone by partly suppressing bone formation.

INTRODUCTION

Glucose-dependent insulinotropic polypeptide (GIP) is a gut hormone released from enteroendocrine K cells that enhances insulin secretion after food intake¹. The GIP receptor is expressed in pancreatic β -cells, and other tissues including adipose tissue and bone^{2–4}. We previously generated GIP-deficient mice, and found that GIP deficiency protected the mice from high-fat diet-induced obesity and insulin resistance⁵, suggesting that blocking GIP signaling might be a strategy to treat obesity. However, mice lacking GIP showed signs of osteopenia, characterized by reduced bone volume, reduced number of trabeculae and increased osteoclast numbers⁵. Ovariectomy accelerates osteopenia and fat accumulation in the abdominal region^{6,7}, and leads to metabolic abnormalities, such as insulin resistance and dyslipidemia^{8,9}; however, the mechanisms remain unclear. To further investigate the role of GIP in fat, glucose and bone metabolism, we evaluated the effect of GIP deficiency on

adipose tissue and bone metabolism in the setting of ovariectomy in mice.

METHODS

Animal care and procedures were approved by Kyoto University Animal Care Committee (MedKyo16584).

GIP gene expression was reduced in C57BL/6J $GIP^{Gfp/+}$ mice or was entirely absent in $GIP^{Gfp/Gfp}$ mice compared with wild-type (WT) mice, which were all housed as described previously⁵. Surgical ovariectomies (dorsal approach) were carried out on female WT, $GIP^{Gfp/+}$ and $GIP^{Gfp/Gfp}$ mice at the age of 8 weeks. Experiments were carried out on three separate cohorts of mice, each consisting of three groups of five to seven mice. Body fat mass, food intake along with energy expenditure and locomotor activity were measured as described previously^{10,11}. Oral glucose tolerance tests (OGTTs) were carried out at 17 and 37 weeks-of-age using 2 g/kg body weight glucose, and insulin tolerance tests were carried out at 24 and 40 weeks-of-age using 0.5 U/kg regular insulin as described previously¹⁰. Plasma insulin, total GIP and glucagon-like polypeptide-1 (GLP-1) levels were measured using a mouse

[†]These authors contributed equally to this article.

Received 2 July 2018; revised 14 November 2018; accepted 15 November 2018

insulin enzyme-linked immunosorbent assay kit (Shibayagi, Gunma, Japan), GIP enzyme-linked immunosorbent assay kit (EMD Millipore Corporation, Billerica, MA, USA) and total GLP-1 enzyme-linked immunosorbent assay kit (Meso Scale Discovery, Rockville, MD, USA), respectively. Bone analysis by dual-energy X-ray absorptiometry and microcomputed tomography (μ CT; LCT-100M, Aloka, Tokyo, Japan), and the measurement of plasma osteocalcin and C-terminal telopeptide of type I collagen using a mouse osteocalcin EIA kit (Biomedical Technologies Inc., Stoughton, MA, USA) and RatLaps™ EIA kit (Immunodiagnostic Systems Inc, Gaithersburg, MD, USA) were carried out at 16 weeks-of-age. The blood samples were collected from the tail vein without anesthesia.

All data are expressed as the mean \pm standard error of the mean. Statistical analysis was carried out using one-way ANOVA with the Tukey–Kramer multiple comparison test. *P*-values <0.05 were considered significant.

RESULTS

Body weight gain after ovariectomies was tracked in cohort 2 (Figure 1a). The body weight of GIP^{gfp/gfp} mice was significantly lower than WT mice from 25 weeks-of-age, but there was no difference between WT and GIP^{gfp/+} mice throughout the study. As expected, the uterus showed atrophy in all ovariectomized mice (data not shown). Both subcutaneous and visceral fat depots were reduced by $\sim 40\%$ in GIP^{gfp/gfp} mice, but not significantly reduced in GIP^{gfp/+} mice compared with those in WT mice at 26 weeks-of-age in cohort 1 (Figure 1b). Lean body weight, food intake, locomotor activity and energy expenditure were not different among all three groups (Figure 1b–e).

Blood glucose levels during OGTTs at 17 weeks-of-age in cohort 1 were not different (Figure 2a). Insulin levels were decreased at 30 min after glucose administration in GIP^{gfp/gfp} mice compared with WT mice, but the area under the curves (AUC) of plasma insulin responses were not different (Figure 2b). The AUC of plasma GIP were under the detection level in GIP^{gfp/gfp} mice, and the AUC of GIP responses were similar in WT and GIP^{gfp/+} (Figure 2c,g). By 37 weeks-of-age in cohort 2, blood glucose levels were significantly decreased in GIP^{gfp/gfp} mice compared with WT, resulting in a lower AUC (Figure 2e). In contrast, insulin responses to oral glucose were not different among the three groups (Figure 2f). Plasma GLP-1 levels during OGTT were not significantly different in WT and GIP^{gfp/gfp} mice (15.81 ± 2.55 and 11.95 ± 6.26 pg/dL at 15 min after OGTT, respectively). There were no differences in glucose reduction in response to exogenous insulin administration among the three groups at either 24 or 40 weeks-of-age (Figures 2d,h). The ovariectomized WT mice showed GIP hypersecretion, obesity and insulin resistance compared with non-ovariectomized WT mice (Figure S1).

At 16 weeks-of-age in cohort 3, body length and bone mineral density measured by dual-energy X-ray absorptiometry, whole and cortical bone mineral density as determined by microcomputed tomography, and plasma C-terminal

telopeptide of type I collagen levels were not different between the three groups (Table 1). However, cancellous bone mineral density, cortical thickness and plasma osteocalcin levels were decreased by 64%, 50% and 38% in GIP^{gfp/gfp} mice compared with WT mice, respectively. Cortical thickness and plasma osteocalcin levels were decreased by 43% and 27% in GIP^{gfp/gfp} mice compared with GIP^{gfp/+} mice, respectively, whereas there was no difference in GIP^{gfp/+} mice compared with WT mice.

DISCUSSION

Ovarian hormone deficiency increases abdominal fat, insulin resistance and osteopenia^{8,9,12}. We investigated the role of GIP in a rodent ovariectomy model, and the combined effect of ovarian hormone deficiency and GIP deficiency. We found that weight gain, subcutaneous and visceral fat mass, cancellous bone mineral density, bone cortical thickness, and plasma osteocalcin levels were reduced in GIP knockout mice compared with WT mice. These results are consistent with previous findings in GIP receptor knockout mice, GIP receptor antagonists, chemical K-cell ablation, and GIP antibody therapy showing the anabolic effect of GIP on adipose tissue^{5,13–15} and bone¹⁶.

Although we did not detect significant changes in food intake or locomotor activity, we cannot exclude the possibility that small reductions in food intake or increase in locomotor activity contributed to reduced weight gain in GIP^{gfp/gfp} mice. We also observed improved glucose intolerance in GIP^{gfp/gfp} mice aged 37 weeks-of-age compared with WT mice with the same magnitude of insulin responses, whereas no difference was seen at 17 weeks-of-age. Perhaps the significantly lower body weight and lower visceral fat mass in GIP^{gfp/gfp} mice compared with WT mice after 26 weeks-of-age might have contributed to these results. We have previously reported that GLP-1 secretion remained unchanged in GIP^{gfp/gfp} mice⁵, and the present study also showed no compensatory hypersecretion of GLP-1 in the ovariectomized GIP-deficient mice.

We did not detect any improvement in insulin sensitivity, which might have been expected with reduced fat accumulation, but we cannot exclude the possibility of subtle changes in insulin sensitivity that could not be detected by our whole-body insulin tolerance tests. We speculate that glucose homeostasis is not dramatically impaired in the GIP-deficient mice, because lower body weight and visceral fat mass improved insulin sensitivity.

The present study did not show any significant changes in glucose and bone metabolism in GIP^{gfp/+} mice compared with WT mice. These results were different from previous findings on partial reduction of GIP signaling^{5,17}. Although we used GIP^{gfp/+} mice in which GIP levels were reduced before ovariectomies (Figure S2), the levels of GIP at OGTT were similar to that of WT mice after ovariectomies. The mechanisms of how ovariectomy might influence GIP production in GIP^{gfp/+} mice are unknown, but potentially, changes in estrogen or gonadotropin hormones might alter GIP secretion.




Figure 1 | The phenotype of ovariectomized mice. (a) Body weight tracking after ovariectomies in cohort 2 ($n = 7$), (b) fat weight and lean body weight, (c) food intake, (d) locomotor activity, and (e) energy expenditure at 26 weeks-of-age for cohort 1 ($n = 6$). (a) $*P < 0.05$ compared with wild-type mice (WT; white circles and bars). (b–e) $*P < 0.05$, $**P < 0.01$. GFP, green fluorescent protein; GIP^{gfp/+} green fluorescent protein inserted into the glucose-dependent insulinotropic polypeptide locus, in which glucose-dependent insulinotropic polypeptide locus was reduced (gray circles and bars); GIP^{gfp/gfp} glucose-dependent insulinotropic polypeptide locus was absent (black circles and bars); NS, not significantly different.

Regarding the role of GIP on bone metabolism, reduced bone formation, decreased bone strength and bone quality have been reported in GIP receptor knockout mice^{18–21}, and conversely, GIP-overexpressing transgenic mice showed increased bone mass²². Although there is a report of osteocalcin-induced release of glucagon-like peptide-1²³, no report that GIP regulates osteocalcin directly exists as far as we know. Ovarian hormone deficiency induced osteopenia itself, but GIP deficiency enhanced osteopenia, particularly in cancellous bone by partly

suppressing bone formation. We have to consider not only estrogen deficiency, but also elevated gonadotropins might contribute to bone metabolism. There are very few reports of the relationship between GIP and estrogen deficiency. In humans, plasma GIP levels were approximately twice as high in postmenopausal women as young premenopausal women²⁴, and estrogen replacement therapy reduced plasma GIP levels in postmenopausal women²⁵. We could investigate only a part of the relationship between GIP and estrogen in the present study,











Figure 2 | Oral glucose tolerance tests (OGTTs) and insulin tolerance tests (ITTs) in ovariectomized mice. OGTT and ITT in wild-type (WT; white circles and bars), green fluorescent protein inserted into the glucose-dependent insulinotropic polypeptide (GIP) locus, in which the GIP locus was reduced (GIP^{gfp/+}; gray circles and bars) and absent (GIP^{gfp/gfp}; black circles and bars) mice. OGTTs were carried out at (a–c) 17 weeks-of-age in cohort 1 ($n = 6$) and (e–g) 37 weeks-of-age in cohort 2 ($n = 7$). ITTs were carried out at (d) 24 weeks in cohort 1 ($n = 4$) and (h) 40 weeks in cohort 2 ($n = 7$). (a,e) Blood glucose levels, (b,f) plasma insulin levels during OGTTs, (c,g) plasma total GIP levels during OGTTs and (d,h) blood glucose levels during ITTs as the percentage change from fasting glucose levels. The area under the curves (AUC) are shown in the upper right panel of each figure. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ compared with WT. NS, not significantly different.

Table 1 | Bone analysis in ovariectomized mice

	WT	GIP ^{gfp/+}	GIP ^{gfp/gfp}
Body length (cm)	9.4 ± 0.02	9.4 ± 0.06	9.4 ± 0.07
Body weight (g)	25.5 ± 0.82	25.8 ± 1.02	23.5 ± 0.72
BMD (g/cm ³)	22.2 ± 1.1	23.6 ± 1.5	20.7 ± 1.3
Whole BMD (mg/cm ³)	360.3 ± 28.2	325.5 ± 8.0	308.4 ± 19.6
Cortical BMD (mg/cm ³)	358.9 ± 22.7	331.7 ± 9.3	332.8 ± 6.3
Cancellous BMD (mg/cm ³)	287.8 ± 63.7	148.3 ± 14.3	104.4 ± 22.4*
Cortical thickness (cm)	0.074 ± 0.008	0.066 ± 0.009	0.038 ± 0.001**, ***
Plasma osteocalcin (ng/mL)	47.8 ± 3.1	40.1 ± 3.2	29.4 ± 2.1*, ***
Plasma CTx (ng/mL)	16.9 ± 0.71	17.0 ± 0.53	17.9 ± 0.51

Data presented as the mean ± standard error of the mean. BMD, bone mineral density; CTx, C-terminal telopeptide of type I collagen. * $P < 0.05$ versus wild-type mice (WT). ** $P < 0.01$ versus WT. *** $P < 0.05$ versus green fluorescent protein (GFP) inserted into the glucose-dependent insulinotropic polypeptide (GIP) locus, in which the GIP locus was reduced (GIP^{gfp/+}) and absent (GIP^{gfp/gfp}) mice.

but the mechanism by which estrogen modulates GIP production requires further study.

In conclusion, the present study supports the concept that the total elimination of GIP might reduce weight gain and improve glucose metabolism, but could be associated with undesirable consequences on bone loss in the setting of ovariectomy in mice.

ACKNOWLEDGMENTS

The authors thank Mr Shoichi Asano for technical assistance. This work was supported by JSPS Core-to-Core Program, A. Advanced Research Networks; JSPS KAKENHI Grant Numbers JP18K16197; grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); Japan Society for the Promotion of Science; Ministry of Health, Labour, and Welfare; Ministry of Agriculture, Forestry and Fisheries; Japan Diabetes Foundation; Japan Association for Diabetes Education and Care; MSD life science foundation; and Japan Foundation for Applied Enzymology.

DISCLOSURE

NI served as a medical advisor for Takeda, Taisho, GlaxoSmithKline and Mitsubishi Tanabe; lectured for MSD, Sanofi, Novartis, Dainippon Sumitomo, Kyowa Kirin and Mitsubishi Tanabe; and received payment for services, outside the submitted work. The other authors declare no conflict of interest.

REFERENCES

1. Cho YM, Kieffer TJ. K-cells and glucose-dependent insulinotropic polypeptide in health and disease. *Vitam Horm* 2010; 84: 111–150.
2. Usdin TB, Mezey E, Button DC, *et al.* Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. *Endocrinology* 1993; 133: 2861–2870.
3. Bollag RJ, Zhong Q, Phillips P, *et al.* Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. *Endocrinology* 2000; 141: 1228–1235.
4. Joo E, Harada N, Yamane S, *et al.* Inhibition of Gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high fat diet-fed mice. *Diabetes* 2017; 66: 868–879.
5. Nasteska D, Harada N, Suzuki K, *et al.* Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. *Diabetes* 2014; 63: 2332–2343.
6. Thurston RC, Sowers MR, Sternfeld B, *et al.* Gains in body fat and vasomotor symptom reporting over the menopausal transition: the study of women's health across the nation. *Am J Epidemiol* 2009; 170: 766–774.
7. Van Pelt RE, Gavin KM, Kohrt WM. Regulation of body composition and bioenergetics by estrogens. *Endocrinol Metab Clin North Am* 2015; 44: 663–676.

8. Carr MC. The emergence of the metabolic syndrome with menopause. *J Clin Endocrinol Metab* 2003; 88: 2404–2411.
9. Mayes JS, Watson GH. Direct effects of sex steroid hormones on adipose tissues and obesity. *Obes Rev* 2004; 5: 197–216.
10. Shimazu-Kuwahara S, Harada N, Yamane S, *et al.* Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in *ob/ob* mice. *Mol Metab* 2017; 6: 288–294.
11. Park SY, Kim MJ, Kim YJ, *et al.* Selective PCAF inhibitor ameliorates cognitive and behavioral deficits by suppressing NF- κ B-mediated neuroinflammation induced by A β in a model of Alzheimer's disease. *Int J Mol Med* 2015; 35: 1109–1118.
12. Garnero P, Sornay-Rendu E, Chapuy MC, *et al.* Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. *J Bone Miner Res* 1996; 11: 337–349.
13. Miyawaki K, Yamada Y, Ban N, *et al.* Inhibition of gastric inhibitory polypeptide signaling prevents obesity. *Nat Med* 2002; 8: 738–742.
14. McClean PL, Irwin N, Cassidy RS, *et al.* GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. *Am J Physiol Endocrinol Metab* 2007; 293: E1746–E1755.
15. Boylan MO, Glazebrook PA, Tatalovic M, *et al.* Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice. *Am J Physiol Endocrinol Metab* 2015; 309: E1008–E1018.
16. Bollag RJ, Zhong Q, Ding KH, *et al.* Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. *Mol Cell Endocrinol* 2001; 177: 35–41.
17. McClean PL, Irwin N, Hunter K, *et al.* (Pro(3))GIP[mPEG]: novel, long-acting, PEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. *Br J Pharmacol* 2008; 155: 690–701.
18. Tsukiyama K, Yamada Y, Yamada C, *et al.* Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. *Mol Endocrinol* 2006; 20: 1644–1651.
19. Xie D, Cheng H, Hamrick M, *et al.* Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. *Bone* 2005; 37: 759–769.
20. Mieczkowska A, Irwin N, Flatt PR, *et al.* Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. *Bone* 2013; 56: 337–342.
21. Gaudin-Audrain C, Irwin N, Mansur S, *et al.* Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice. *Bone* 2013; 53: 221–230.
22. Xie D, Zhong Q, Ding KH, *et al.* Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. *Bone* 2007; 40: 1352–1360.
23. Mizokami A, Yasutake Y, Gao J, *et al.* Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. *PLoS ONE* 2013; 8: e57375.
24. Ranganath L, Sedgwick I, Morgan L, *et al.* The ageing entero-insular axis. *Diabetologia* 1998; 41: 1309–1313.
25. Sztefko K, Rogatko I, Milewicz T, *et al.* Effect of hormone therapy on the enteroinsular axis. *Menopause* 2005; 12: 630–638.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1 | OGTT and ITT in ovariectomized WT (WT) mice and non-ovariectomized WT (WT sham) mice ($n = 4-6$). Body weight of WT mice and WT sham mice were 44.2 ± 2.1 g and 28.2 ± 1.4 g, respectively ($P < 0.01$). * $P < 0.05$, ** $P < 0.01$ compared to WT sham. GIP, glucose-dependent insulinotropic polypeptide; HOMA-IR, homeostasis model assessment of insulin resistance; WT, wild-type. Data are expressed as means \pm standard error of the mean.

Figure S2 | OGTT in female 9 weeks of age in WT, GIP^{gfp/+} and GIP^{gfp/gfp} mice ($n = 7$). * $P < 0.05$, ** $P < 0.01$ compared to WT. GIP, glucose-dependent insulinotropic polypeptide; GFP, green fluorescent protein; WT, wild-type. Data are expressed as means \pm standard error of the mean.